Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

The disease is driven by accumulation of precursor B lymphoblasts, producing both marrow/leukemic disease and extramedullary tumor lesions. The supplied literature emphasizes immune-evasion and treatment-resistance mechanisms in this disease context, including tumor antigen escape, drug resistance, and tumor escape. Co-studied targets such as T-cell receptors, chimeric antigen receptors, and cytokines reflect the central role of immune recognition and immune-based therapy in its biology.

The supplied literature supports immunotherapy-based treatment approaches for B-cell lymphoblastic leukemia/lymphoma, especially CAR-T cell therapy targeting CD19 in relapsed or refractory disease. Bispecific T-cell engager therapy, such as blinatumomab, is also described as a targeted immuno-oncology approach that links T cells to malignant B cells. These modalities are discussed in the context of overcoming antigen escape and resistance.